Alternatives to adalimumab
FDA shortage status is active for adalimumab; 4 same-class SPL records are listed below for registry comparison only.
Brand: Humira
adalimumab class peers while FDA lists an active shortage
adalimumab (Humira) is on an FDA shortage listing while 4 other TNF-Alpha Inhibitor (Biologic) SPL records remain in this registry peer set (class inventory 5). Labeled indication field for adalimumab: Idacio can help adults with rheumatoid arthritis by reducing joint pain and damage.
Top FAERS reaction fields for adalimumab total 349,859 reports across 10 reactions, set beside certolizumab, etanercept, golimumab. Counts are exposure-weighted submissions, not per-patient risk.
About adalimumab
Idacio is a medicine that blocks a protein called TNF. It is used to treat several diseases, including arthritis and Crohn's disease.
Used for: Idacio can help adults with rheumatoid arthritis by reducing joint pain and damage. It can also help children (2 years and older) with juvenile idiopathic arthritis. Idacio treats psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa and uveitis.
4 TNF-Alpha Inhibitor (Biologic) peers (wide set)
certolizumab
RxCimzia
Cimzia treats Crohn's disease by easing symptoms. It also helps keep the disease under control in adults. Cimzia can also treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis in adults. It is also used for juvenile idiopathic arthritis in children 2 years and older.
etanercept
RxEnbrel
Enbrel treats rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis in adults. It also treats juvenile idiopathic arthritis, juvenile psoriatic arthritis and plaque psoriasis in children. Enbrel helps to reduce the signs and symptoms of these conditions, like pain and swelling. It can also help to prevent further damage to your joints.
golimumab
RxSimponi
Simponi Aria treats rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis. It can help reduce pain, swelling, and stiffness in your joints. For rheumatoid arthritis, you will take this medicine with methotrexate.
infliximab
RxRemicade
Inflectra treats Crohn's disease in adults and children (6+). It helps reduce symptoms and keep the disease under control. It also treats ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.
adalimumab vs certolizumab & etanercept · FAERS reaction fields
FAERS top-reaction field "Rheumatoid Arthritis" shows the widest count spread between adalimumab and certolizumab, etanercept, golimumab in this extract (10,602-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.
| Side Effect | adalimumab | certolizumab | etanercept | golimumab |
|---|---|---|---|---|
| Pain | 49,062 | - | 43,004 | 13,403 |
| Arthralgia | 48,039 | - | 44,971 | 9,679 |
| Injection Site Pain | 47,251 | - | 56,664 | - |
| Fatigue | 39,111 | - | 30,269 | 11,277 |
| Rheumatoid Arthritis | 35,573 | - | 46,175 | 14,100 |
| Headache | 28,330 | - | 24,668 | - |
| Nausea | 27,102 | - | 19,211 | - |
| Diarrhoea | 25,413 | - | - | - |
"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.
adalimumab shortage vs TNF-Alpha Inhibitor (Biologic) peer index
Shortage status
FDA shortage listing is active for adalimumab (status: To Be Discontinued). Peer rows remain a registry index, not a switch guide.
Frequently Asked Questions
Does FDA list a shortage for adalimumab while peers remain indexed? ▼
Registry note: Shortage listings and peer indexes are for registry orientation only. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.
Field note for adalimumab: see also the generic vs brand label guide when reading Humira SPL strings.
Read our methodology - how this data is sourced, computed, and verified.